Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.0252W HIGH $7.13
Volume
156.51 K
Value Traded
1.18 M
Short % Float
19.63%
+5.63%Week
+1.03%1 Month
-14.35%3 Month
+67.66%6 Month
-42.53%5 Year
-79.17%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
397.35 M
EPS (TTM)
-0.28
P/E Ratio
-
Ent. Value
384.08 M
Total Shares
100.85 M
Float Shares
47.55 M
Insiders
52.85%
Institutions
15.51%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
GALT Catalyst Timeline
Dated clinical, regulatory and corporate events for Galectin Therapeutics Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Galectin Therapeutics Inc.
728Total events
7Upcoming
124Tier-1 (high impact)
2012 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Timing GuidancebelapectinPresentation
Submission of registrational Phase 3 protocol for belapectin to FDA for prevention of disease progression in MASH cirrhosis and portal hypertension
MASH cirrhosis and portal hypertensionsource ↗
●R&D DayPresentation
Galectin management to present at H.C. Wainwright 28th Annual Global Investment Conference
◆Trial InitiationbelapectinTrial
Registrational Phase 3 trial protocol submission anticipated
MASH cirrhosis and portal hypertensionsource ↗
◆Timing GuidancebelapectinPresentation
Registrational Phase 3 trial protocol submission anticipated in 3Q 2026
MASH cirrhosis and portal hypertensionsource ↗
▲FDA Feedback ReceivedbelapectinFDA Meeting
FDA agreement on key elements of planned Phase 3 trial design for belapectin
MASH cirrhosis and portal hypertensionsource ↗
▲Type C MeetingbelapectinFDA Meeting
Positive Type C meeting with FDA on belapectin Phase 3 program
MASH cirrhosis and portal hypertensionsource ↗
▲FDA Feedback ReceivedbelapectinFDA Meeting
FDA accepted central endoscopy review methodology for Phase 3
MASH cirrhosis and portal hypertensionsource ↗
●AdCom ScheduledbelapectinAdvisory Committee
Hosted advisory committee meeting at SOLAR conference
MASH cirrhosissource ↗
●Other Regulator MilestonebelapectinEx-US Regulatory
Advisory committee meeting at SOLAR conference
MASH cirrhosissource ↗
◆Oral PresentationbelapectinPresentation
Oral presentation: Belapectin reduces varices development in high-risk MASH cirrhosis by modulating fibrogenesis balance as reflected by Pro-C3/CTX-III ratio
MASH cirrhosissource ↗
◆Poster PresentationbelapectinPresentation
Poster presentation: Risk reduction in clinically significant portal hypertension with belapectin in advanced MASH cirrhosis: results from the NAVIGATE trial
MASH cirrhosissource ↗
▲Oral PresentationbelapectinPresentation
Oral presentation at EASL 2026 on belapectin's impact on fibrosis modulation in high-risk MASH cirrhosis
MASH cirrhosissource ↗
▲Poster PresentationbelapectinPresentation
Poster presentation at EASL 2026 on risk reduction in clinically significant portal hypertension; designated TOP Poster
MASH cirrhosissource ↗
▲Full ResultsbelapectinClinical Data
Publication of NAVIGATE Phase 2b trial results for belapectin in Journal of Hepatology
MASH cirrhosis and portal hypertensionsource ↗
◆Oral PresentationbelapectinPresentation
Data presentations at EASL later this month
MASH cirrhosis and portal hypertensionsource ↗
◆Type C MeetingbelapectinFDA Meeting
In-person Type-C meeting with FDA to align on next steps for belapectin program
MASH cirrhosissource ↗
◆Type B MeetingbelapectinFDA Meeting
FDA meeting in Q2 2026 to align on next steps for belapectin program
MASH cirrhosissource ↗
▲Runway Guidance UpdateCorporate
Cash runway extended through April 2027 via $10M line of credit
▲Management ChangeCorporate
Appointment of Henry Brem, M.D. as independent director to Board of Directors
◆Oral PresentationbelapectinPresentation
Virtual KOL event to discuss belapectin development program and updated NAVIGATE Phase 3 results
MASH cirrhosis and portal hypertensionsource ↗
●R&D DaybelapectinPresentation
Virtual KOL event on MASH cirrhosis and belapectin clinical development
MASH cirrhosissource ↗
▲PublicationbelapectinPresentation
Publication in Hepatology of NAVIGATE trial results
MASH cirrhosissource ↗
▲Oral PresentationbelapectinPresentation
Oral presentation at EASL 2026 on fibrosis modulation
MASH cirrhosissource ↗
▲Poster PresentationbelapectinPresentation
Poster presentation at EASL 2026 on portal hypertension risk reduction
MASH cirrhosissource ↗
◆FDA Feedback ReceivedbelapectinFDA Meeting
FDA feedback on NAVIGATE data package anticipated by year-end 2025
MASH cirrhosissource ↗
●Type C MeetingbelapectinFDA Meeting
FDA provided written response to Type C meeting request for belapectin development program
MASH cirrhosis and portal hypertensionsource ↗
▲Equity OfferingCorporate
Entered into $10 million convertible line of credit financing agreement with chairman Richard E. Uihlein
◆FDA Feedback ReceivedbelapectinFDA Meeting
FDA package submitted; feedback anticipated soon
MASH cirrhosis and portal hypertensionsource ↗
◆Poster PresentationbelapectinPresentation
Poster presentation of NAVIGATE trial results at AASLD 2025
compensated MASH cirrhosis and portal hypertensionsource ↗
◆Oral PresentationbelapectinPresentation
Belapectin Reduces Liver Stiffness Progression and Prevents Varices at 18 Months in MASH Cirrhosis: Results from the NAVIGATE Trial
MASH cirrhosissource ↗
◆Full ResultsbelapectinClinical Data
NAVIGATE trial 18-month and 36-month results presented at AASLD 2025
compensated MASH cirrhosis and portal hypertensionsource ↗
◆Poster PresentationbelapectinPresentation
Belapectin Maintains a Favorable Trend in Reducing Variceal Development Over 36 Months in MASH Cirrhosis: Results from the NAVIGATE Trial
MASH cirrhosissource ↗
◆Oral PresentationPresentation
Company presentation at H.C. Wainwright 9th Annual MASH Investor Conference
MASHsource ↗
◆Oral PresentationPresentation
Company presentation at H.C. Wainwright 27th Annual Global Investment Conference
◆Oral PresentationbelapectinPresentation
Prepare to present data to FDA in fall 2025
MASH cirrhosissource ↗
◆FDA Feedback ReceivedbelapectinFDA Meeting
FDA meeting expected in first half of 2025 to discuss NAVIGATE results and next steps
MASH cirrhosis with portal hypertensionsource ↗
◆Oral PresentationbelapectinPresentation
Virtual KOL event discussing belapectin NAVIGATE Phase 3 trial results
MASH cirrhosis and portal hypertensionsource ↗
◆Topline ReadoutbelapectinClinical Data
NAVIGATE trial 18-month primary analysis results in ITT population
MASH cirrhosis with portal hypertensionsource ↗
Past FDA Catalysts and PDUFA Decisions
How GALT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-05-27 | belapectin | Phase 2b/3 data readout | Phase 2b/3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D39 / 100
Pipeline Score
$37M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.1x
rNPV / MCap
Top 41%
Micro Cap(rank 271 of 660)
Percentile Rank
Galectin Therapeutics Inc. faces pipeline headwinds (39/100), with $801M risk-adjusted pipeline value, led by GR-MD-02 in Psoriasis (Phase 2), across $71B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GR-MD-02 Small moleculeCompletedNCT02421094 | Nonalcoholic Steatohepatitis | Phase 2 | COMPLETED | 30 | Sep 27, 2016 |
Clinical Trial Results
Readouts, endpoints and source filings for every GALT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| belapectin Fast Track | advanced MASH cirrhosis | 2026-05-27 | p=0.04; 11.7% vs. 23.9%; p=0.03; p=0.0073Read More | Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH CirrhosisRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Uihlein Richard EDirector, 10% Owner | Option | 31,825,235 42,162,911 held | $3.00 | 07/31/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in GALT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| GREAT POINT PARTNERS LLC | 0.7 % (40 %) | 3.71 M | 800.00 K |
GALT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How GALT ranks across every disease it competes in
Competitive Position is a premium feature
See how GALT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialGALT News
GALTGalectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026
Galectin Therapeutics announced its participation in the AASLD Liver Meeting 2026, where it will present findings from its NAVIGATE and GT-026 Phase 2b trials. The company will deliver an oral presentation and two poster presentations, highlighting noninvasive risk analyses related to MASH cirrhosis and portal hypertension. Additionally, a registrational protocol for a Phase 3 trial of belapectin has been submitted to the FDA.
Read more →GALTGalectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Galectin Therapeutics, Inc. will present at the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026, in New York. The presentation will include a company overview and one-on-one meetings with investors. The company is known for its lead drug, belapectin, aimed at treating chronic liver disease and cancer.
Read more →GALTGalectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
Galectin Therapeutics reported positive financial results for Q2 2026, highlighting an agreement with the FDA on the Phase 3 trial of belapectin for MASH cirrhosis. The company is preparing to submit the trial protocol and has seen validation of its NAVIGATE trial data. However, it reported an increased net loss compared to the previous year.
Read more →GALTGalectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet
Galectin Therapeutics has successfully converted $105.8 million in debt into equity, significantly enhancing its financial position. This conversion, executed by Chairman Richard E. Uihlein, involved the issuance of over 34 million shares of common stock. The move is expected to bolster the company's ability to advance its clinical programs, particularly in treating liver fibrosis and portal hypertension.
Read more →GALT▲ +11.4%on this news· ran to +78% by day 3
Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension
Galectin Therapeutics announced a positive Type C meeting with the FDA regarding belapectin for treating MASH cirrhosis and portal hypertension. The FDA agreed on the primary endpoint and regulatory pathway for a Phase 3 trial, which is set to be filed in Q3 2026. The trial aims to assess the drug's efficacy in preventing disease progression, addressing significant unmet medical needs in this patient population.
Read more →GALTGalectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis
Galectin Therapeutics presented new findings at EASL 2026 regarding belapectin's efficacy in modifying disease progression in patients with advanced MASH cirrhosis. The NAVIGATE trial data demonstrated that belapectin significantly reduces the development of varices and improves liver stiffness. The poster presentation was recognized as a TOP Poster, underscoring its importance in the field.
Read more →GALT▼ -7.7%on this news
Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update
Galectin Therapeutics reported its financial results for Q1 2026, highlighting advancements in its belapectin program targeting MASH cirrhosis. The company presented encouraging data supporting the drug's potential efficacy, and it is preparing for significant upcoming data presentations and an FDA meeting. Despite these positive developments, Galectin faces challenges, including ongoing operating losses and the uncertainties inherent to clinical trials. The company's focus remains on establishing partnerships and securing further funding to advance its pipeline.
Read more →GALT▲ +5.2%on this news
Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology
Galectin Therapeutics has published results from its NAVIGATE Phase 2b trial of belapectin, demonstrating a numerical reduction in new esophageal varices in patients with MASH cirrhosis and portal hypertension. The study showed statistically significant results in the per-protocol population, alongside favorable safety and tolerability. These findings support the continued development of belapectin as a potential treatment for this patient population.
Read more →GALTGalectin Therapeutics, Inc. Investigated by the Portnoy Law Firm
Galectin Therapeutics, Inc. is under investigation by the Portnoy Law Firm for potential securities fraud following a substantial drop in stock price. The decline, which saw shares fall by 28.9%, was triggered by adverse regulatory news regarding their primary drug, belapectin. The U.S. FDA's change in engagement from direct discussions to written responses amidst unresolved trial design elements has raised significant investor concerns. The law firm is seeking to represent investors who suffered losses due to these issues.
Read more →GALT▲ +8.6%on this news
Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update
Galectin Therapeutics reported its 2025 financial results, highlighting advancements in the belapectin program. The company is encouraged by findings from the NAVIGATE dataset related to MASH cirrhosis and portal hypertension. Financially, Galectin secured a $10 million line of credit to extend its cash runway through April 2027. The company anticipates an FDA meeting to discuss the program's future.
Read more →GALTGalectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.
Galectin Therapeutics has appointed Dr. Henry Brem as an independent director to its Board of Directors. Dr. Brem is a renowned neurosurgeon-scientist with significant experience in translational medicine. His expertise is expected to support Galectin's strategic priorities, particularly in advancing their lead drug, belapectin, for MASH cirrhosis and portal hypertension.
Read more →GALTGalectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET
Galectin Therapeutics Inc. announced a virtual key opinion leader (KOL) event scheduled for March 10, 2026, to discuss the development of belapectin for treating metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. The event will highlight significant findings from the NAVIGATE Phase 3 clinical trial, which emphasize belapectin's antifibrotic and disease-modifying capabilities. This development comes at a critical time given the lack of approved therapies for managing varices in MASH cirrhosis.
Read more →GALT▼ -8%on this news
Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027
Galectin Therapeutics has received a written response from the FDA regarding its development program for belapectin, indicating alignment on the proposed patient population for a registration trial. The company plans to hold a follow-up Type C meeting to finalize clinical trial design and present new biomarker data. Additionally, Galectin has secured a $10 million line of credit to support its operations through March 2027.
Read more →GALTThanks Kevin, Since I became President and CEO of Galectin Therapeutics, I can honestly say that I have never been as excited as I am today, nor have I had the luxury of sharing such an extensive amount of meaningful inf
Galectin Therapeutics has announced exciting developments as the company trades near multi-year highs. The CEO expressed gratitude towards the team and KOLs for their contributions to the NAVIGATE trial, which is generating promising results, particularly regarding belapectin's impact on patients with compensated MASH cirrhosis and portal hypertension. Key findings from the trial indicate potential benefits in reducing disease progression and improving clinical outcomes. The company is actively enhancing its data presentation and exploring strategic opportunities moving forward.
Read more →GALTGalectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update
Galectin Therapeutics reported its financial results for the quarter ending September 30, 2025, highlighting promising data from its NAVIGATE trial for belapectin. The results indicate encouraging consistency across key biomarkers related to the drug's antifibrotic activity in patients with compensated MASH cirrhosis. The company is anticipating FDA guidance on next steps and seeks to improve its development programs amid persistent operating losses. Despite financial challenges, the advancements in belapectin's clinical profile suggest potential for impactful treatment in chronic liver disease.
Read more →GALTGalectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting
Galectin Therapeutics presented promising results from the Phase 2 NAVIGATE trial at the AASLD 2025 Annual Meeting. The trial evaluated belapectin, a galectin-3 inhibitor, in patients with compensated MASH cirrhosis and portal hypertension. Results indicated a significant reduction in the incidence of new varices and improvements in key biomarkers over 36 months, highlighting belapectin's potential as a disease-modifying therapy.
Read more →GALTGalectin Therapeutics to Present at the H.C. Wainwright 9th Annual MASH Investor Conference
Galectin Therapeutics will present at the H.C. Wainwright 9th Annual MASH Investor Conference on October 21, 2025. The management team, including CEO Joel Lewis and CMO Khurram Jamil, will also hold one-on-one meetings with investors. The company focuses on therapies for chronic liver disease and cancer, with its lead drug belapectin targeting galectin-3.
Read more →GALT▲ +7.4%on this news
Galectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025
Galectin Therapeutics announced its participation in the AASLD Liver Meeting 2025, where it will present data from the NAVIGATE trial on belapectin, a treatment targeting MASH cirrhosis. The company's findings indicate that belapectin can reduce liver stiffness progression and prevent varices in patients over the trial duration. The meeting will take place from November 7-11, 2025, in Washington, DC, further reflecting the growing interest in therapies addressing MASH cirrhosis. CEO Joel Lewis expressed optimism about the potential impact of belapectin on treatment options for patients suffering from this condition.
Read more →About Galectin Therapeutics Inc.
Headquarters4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA, 30071
BIOPHARMAWATCH ELITE PLUS
Trade the next GALT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime